加载中
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
前收盘价
US$7.43
−US$0.24 · -3.13%
盘前
US$7.34
−US$0.09 · -1.21%
10月13日 4:00 ET
盘中时间采用ET。市场数据可能有所延迟。
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
日内区间
当前US$7.43
52周区间
当前US$7.43
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.14亿 USD | 1.03亿 USD | 1.56亿 USD | 9802.4万 USD | 2.96亿 USD |
| 销货成本 | 8036万 USD | 1.56亿 USD | 2.38亿 USD | 1.97亿 USD | 1.82亿 USD |
| 毛利 | 3383.6万 USD | −5255.1万 USD | −8136.6万 USD | −9923.5万 USD | 1.14亿 USD |
| 研究与开发 | — | 1.56亿 USD | 2.35亿 USD | — | 1.79亿 USD |
| 销售、一般及管理费用 | 5439.2万 USD | 7187.8万 USD | 7873.9万 USD | 8100.7万 USD | 7635.9万 USD |
| 营业费用 | 5439.2万 USD | 6792.4万 USD | 7818.3万 USD | 8019.2万 USD | 8784万 USD |
| 利息支出 | 5527.3万 USD | 1.18亿 USD | 9792.5万 USD | 6186.3万 USD | 6571.9万 USD |
| 折旧和摊销 | 999.9万 USD | 1334.3万 USD | 1358.8万 USD | 694.6万 USD | 678.8万 USD |
| 营业利润 | −2055.6万 USD | −1.2亿 USD | −1.6亿 USD | −1.79亿 USD | 2574.7万 USD |
| 净利润 | 11.5万 USD | −2.27亿 USD | −2.46亿 USD | −2.2亿 USD | −2392.6万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$25.00
上涨空间 236.47%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2024年4月12日 | 1:20 | — | — |
股票拆分 | 2023年4月26日 | 1,019:1,000 | — | — |
股票拆分 | 2011年10月3日 | 1:6 | — | — |
已生效 2024年4月12日
1:20
已生效 2023年4月26日
1,019:1,000
已生效 2011年10月3日
1:6
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI890.92万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM767.54万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF371.26万0.00%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO174万0.01%180亿 USD0.06%US$112.27-0.35%
First Trust Dow Jones Select MicroCap Index FundFDM116.88万0.45%2.61亿 USD0.65%US$88.895+0.50%
iShares Micro-Cap ETFIWC92.12万0.07%13.17亿 USD0.60%US$181.66-0.73%
iShares Russell 2000 Growth ETFIWO35.09万0.00%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 Value ETFVTWV23.94万0.02%14亿 USD0.06%US$185.97+0.08%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOFirst Trust Dow Jones Select MicroCap Index FundFDMiShares Micro-Cap ETFIWCiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 Value ETFVTWVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
